Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
crawled time : 13:00 source : Www.vynetherapeutics.com save search
SEC Filing: Form 8-K
Published: 2023-05-01 (Crawled : 13:00) - vynetherapeutics.com
VYNE | $2.65 14.22% 12.45% 380K
|
Health Technology
|
| O: 0.0%
H: 18.63%
C: 14.83%
VYNE Therapeutics Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary Fibrosis
Published: 2023-04-19 (Crawled : 13:00) - vynetherapeutics.com
VYNE | $2.65 14.22% 12.45% 380K
|
Health Technology
|
| O: 7.03%
H: 50.75%
C: 33.13%
vyn201 positive fibrosis preclinical therapeutics
VYNE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammation Disease Virtual Conference
Published: 2023-03-22 (Crawled : 13:00) - vynetherapeutics.com
VYNE | $2.65 14.22% 12.45% 380K
|
Health Technology
|
| O: -0.74%
H: 0.37%
C: -5.95%
conference disease therapeutics
VYNE Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Published: 2022-09-06 (Crawled : 13:00) - vynetherapeutics.com
VYNE | $2.65 14.22% 12.45% 380K
|
Health Technology
|
| O: 4.82%
H: 1.15%
C: -3.42%
global conference therapeutics
VYNE Therapeutics to Present at the B&T Cell-Mediated Autoimmune Disease Drug Development Conference
Published: 2022-07-19 (Crawled : 13:00) - vynetherapeutics.com
VYNE | $2.65 14.22% 12.45% 380K
|
Health Technology
|
| O: -0.22%
H: 1.7%
C: 0.0%
drug conference disease therapeutics
VYNE Therapeutics Announces Positive Phase 1b Efficacy Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis
Published: 2022-04-07 (Crawled : 13:00) - vynetherapeutics.com
VYNE | $2.65 14.22% 12.45% 380K
|
Health Technology
|
| O: 13.11%
H: 9.62%
C: -3.19%
fmx114 treatment dermatitis trial therapeutics positive phase 2b
VYNE Investor Relations Presentation
Published: 2022-04-07 (Crawled : 13:00) - vynetherapeutics.com
VYNE | $2.65 14.22% 12.45% 380K
|
Health Technology
|
| O: 13.11%
H: 9.62%
C: -3.19%
presentation
VYNE Reports Positive Preclinical Data for Intra-Articular Injection of Pan-BET Inhibitor, VYN201, in an In Vivo Model of Rheumatoid Arthritis
Published: 2022-03-30 (Crawled : 13:00) - vynetherapeutics.com
VYNE | $2.65 14.22% 12.45% 380K
|
Health Technology
|
| O: -0.81%
H: 10.86%
C: 7.89%
vyn201 preclinical positive injection pre-clinical
VYNE Investor Relations Presentation
Published: 2022-01-19 (Crawled : 13:00) - vynetherapeutics.com
VYNE | $2.65 14.22% 12.45% 380K
|
Health Technology
|
| O: 2.19%
H: 2.99%
C: -5.58%
presentation
Lead BET Inhibitor, VYN201, Demonstrates Improvement in Reducing Fibrotic Tissue Mass and Overall Skin Repair Outcomes in Preclinical Study
Published: 2021-11-04 (Crawled : 13:00) - vynetherapeutics.com
VYNE | $2.65 14.22% 12.45% 380K
|
Health Technology
|
| O: 4.17%
H: 0.67%
C: -8.0%
skin preclinical pre-clinical
VYNE Therapeutics to Report Third Quarter 2021 Financial Results on November 10, 2021
Published: 2021-10-28 (Crawled : 13:00) - vynetherapeutics.com
VYNE | $2.65 14.22% 12.45% 380K
|
Health Technology
|
| O: 0.0%
H: 2.38%
C: 1.59%
financial results results
VYNE Therapeutics Announces Formation of Scientific Advisory Board
Published: 2021-10-21 (Crawled : 13:00) - vynetherapeutics.com
VYNE | $2.65 14.22% 12.45% 380K
|
Health Technology
|
| O: -2.59%
H: 4.42%
C: 2.65%
therapeutics
SEC Filing: Form 8-K
Published: 2021-10-19 (Crawled : 13:00) - vynetherapeutics.com
VYNE | $2.65 14.22% 12.45% 380K
|
Health Technology
|
| O: -0.88%
H: 4.42%
C: -1.77%
VYNE Therapeutics Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis
Published: 2021-10-19 (Crawled : 13:00) - vynetherapeutics.com
VYNE | $2.65 14.22% 12.45% 380K
|
Health Technology
|
| O: -0.88%
H: 4.42%
C: -1.77%
treatment atopic dermatitis dermatitis trial enroll
SEC Filing: Form 10-Q
Published: 2021-08-12 (Crawled : 13:00) - vynetherapeutics.com
VYNE | $2.65 14.22% 12.45% 380K
|
Health Technology
|
| O: -18.69%
H: 3.83%
C: -15.32%
VYNE Therapeutics Announces Approval of AMZEEQ® (Minocycline) and ZILXI® (Minocycline) in Chinese Economic Pilot Zone
Published: 2021-08-02 (Crawled : 13:00) - vynetherapeutics.com
VYNE | $2.65 14.22% 12.45% 380K
|
Health Technology
|
| O: 1.1%
H: 4.0%
C: 0.0%
chinese approval
VYNE Therapeutics Announces Initiation of Investigator Initiated Trial Evaluating AMZEEQ® (Minocycline) with Oral Isotretinoin in Patients with Moderate to Severe Acne
Published: 2021-07-19 (Crawled : 13:00) - vynetherapeutics.com
VYNE | $2.65 14.22% 12.45% 380K
|
Health Technology
|
| O: -3.61%
H: 4.49%
C: 3.0%
acne trial initiated
SEC Filing: Form 10-Q
Published: 2021-05-06 (Crawled : 13:00) - vynetherapeutics.com
VYNE | $2.65 14.22% 12.45% 380K
|
Health Technology
|
| O: -7.08%
H: 1.43%
C: -15.24%
VYNE Therapeutics to Report First Quarter 2021 Financial Results on May 6, 2021
Published: 2021-04-28 (Crawled : 13:00) - vynetherapeutics.com
VYNE | $2.65 14.22% 12.45% 380K
|
Health Technology
|
| O: -0.19%
H: 1.73%
C: 0.0%
financial results results
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.